Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 FOLFOX-HAIC + immunotherapy with or without local consolidation therapy for oligo-residual advanced hepatocellular carcinoma
ChiCTR2500113517Phase 2Recruiting
- Sponsor
- Yueyang Central Hospital
- Start
- Dec 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC) (2 arms), sponsored by Yueyang Central Hospital. Primary endpoint: progression-free survival. Started Dec 2025; status: recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500113517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113517.